Antibody–drug conjugates (ADC) are one of the fastest growing anticancer drugs. This
approach comprises a mAb conjugated to the cytotoxic payload via a chemical linker that …

Antibody–drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal
antibody tethered to a cytotoxic drug (known as the payload) via a chemical linker. The ADC …

Antibody–Drug Conjugates (ADCs) are now established as a major class of therapeutics for
the clinical treatment of cancer. The properties of the linker between the antibody and the …

Covering: January 2013 to September 2018 Sulfur-containing natural products are a large
class of significant functional molecules. Many of these compounds exhibit potent biological …

Nanotechnology has been the latest approach for diagnosis and treatment for cancer, which
opens up a new alternative therapeutic drug delivery option to treat disease. Nanoparticles …

Antibody-drug conjugates (ADCs) are complex engineered therapeutics consisting of
monoclonal antibodies, directed toward tumor-associated antigens, to which highly potent …

Standard cancer therapies sometimes fail to deliver chemotherapeutic drugs to tumor cells
in a safe and effective manner. Nanotechnology takes the lead in providing new therapeutic …

Since the first approval of gemtuzumab ozogamicin (Mylotarg; Pfizer; CD33 targeted), two
additional antibody–drug conjugates (ADC), brentuximab vedotin (Adcetris; Seattle …

As one of the major therapeutic options for cancer treatment, chemotherapy has limited
selectivity against cancer cells. Consequently, this therapeutic strategy offers a small …

Antibody-drug conjugates (ADCs) are cancer therapeutic agents comprised of an antibody,
a linker and a small-molecule payload. ADCs use the specificity of the antibody to target the …